Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia
Authors:
- Gergely ToldiGTGergely Toldi
- Edina BíróEBEdina Bíró
- Balázs SzalayBSBalázs Szalay
- Balázs StenczerBSBalázs Stenczer
- Attila MolvarecAMAttila Molvarec
- János RigóJRJános Rigó
- Barna VásárhelyiBVBarna Vásárhelyi
- Gabriella BekõGBGabriella Bekõ
- 1 January 2011
- journal article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (11) , 1873-6
Abstract
Preeclampsia is characterized by a maternal systemic inflammatory response and the impairment of maternal immune tolerance present in healthy pregnancy. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker increasingly used for the monitoring of systemic inflammation. We aimed to assess the levels of suPAR and other markers of systemic inflammation in preeclampsia compared to healthy pregnancy. We determined plasma suPAR, IL-6 and high sensitivity C-reactive protein (hs-CRP) levels in plasma samples of 62 healthy pregnant and 41 preeclamptic women in the third trimester of pregnancy. Plasma suPAR levels were elevated in preeclampsia [3.18 (2.30-4.71) ng/mL vs. 2.02 (1.81-2.40) ng/mL, p=0.0001, median (interquartile range)]. IL-6 and hs-CRP levels were also higher compared with healthy pregnancy [5.99 (2.97-18.12) pg/mL vs. 1.41 (1.00-2.70) pg/mL, p=0.0001 and 6.60 (3.55-15.40) mg/L vs. 3.90 (2.10-7.25) mg/L, p=0.006, respectively, median (interquartile range)]. Linear regression analyses revealed an association between individual plasma suPAR and log IL-6 levels as well as log hs-CRP levels. suPAR levels are elevated in preeclampsia and vary in a narrower range compared with IL-6 and hs-CRP. ROC analysis indicated that monitoring of suPAR levels is a suitable tool for the detection of systemic inflammation in pregnancy.Keywords
This publication has 12 references indexed in Scilit:
- Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general populationJournal of Internal Medicine, 2010
- Hepcidin concentrations and iron homeostasis in preeclampsiaClinical Chemistry and Laboratory Medicine (CCLM), 2010
- Inflammation and PregnancyReproductive Sciences, 2009
- suPAR: The Molecular Crystal BallDisease Markers, 2009
- Plasma Concentrations of Soluble Urokinase‐Type Plasminogen Activator Receptor Are Increased in Patients with Malaria and Are Associated with a Poor Clinical or a Fatal OutcomeThe Journal of Infectious Diseases, 2005
- Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcomeScandinavian Journal of Infectious Diseases, 2004
- Expression of Urokinase Plasminogen Activator Receptor on Monocytes from Patients with Relapsing-Remitting Multiple Sclerosis: Effect of Glatiramer Acetate (Copolymer 1)Clinical and Diagnostic Laboratory Immunology, 2001
- Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample HandlingThe International Journal of Biological Markers, 2001
- Increased T‐Helper‐1‐Type Immunity and Decreased T‐Helper‐2‐Type Immunity in Patients with PreeclampsiaAmerican Journal of Reproductive Immunology, 1999
- Preeclampsia: An excessive maternal inflammatory response to pregnancyAmerican Journal of Obstetrics and Gynecology, 1999